• Publications
  • Influence
Transport across 1,9-decadiene precisely mimics the chemical selectivity of the barrier domain in egg lecithin bilayers.
The barrier domain solubility-diffusion theory of lipid bilayer permeability relates the permeability coefficient (P(m)) to the solute's partition coefficient (PC(barrier/w)) and diffusionExpand
  • 30
  • 1
Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor.
The crystal polymorphism of Abbott-79175, a potent second-generation 5-lipoxygenase inhibitor, has been studied. Crystallization from an ethyl acetate/heptane system in which moisture content was notExpand
  • 20
  • 1
Independence of substituent contributions to the transport of small-molecule permeants in lipid bilayer
Purpose: To explore the independence of functional group contributions to permeability of nonelectrolytes across egg lecithin bilayers. Methods. The transport rates were measured of a series ofExpand
  • 22
A hydrophobicity scale for the lipid bilayer barrier domain from peptide permeabilities: nonadditivities in residue contributions.
Passive peptide transport across lipid membranes is governed by the energetics of partitioning into the ordered chain interior coupled with the rate of diffusion across this region. A hydrophobicityExpand
  • 20
Procédé de préparation de (3s,4r)-3-éthyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroéthyl)pyrrolidine-1-carboxamide et de ses formes à l'état solide
La presente invention concerne des procedes de preparation de (3S,4R)-3-ethyl-4-(3 H -imidazo[1,2- a ]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, de ses formes aExpand
Formes posologiques sous forme de comprimés
La presente invention concerne des formes posologiques sous forme de comprimes comprenant au moins deux principes actifs differents. Dans un mode de realisation, une forme posologique sous forme deExpand
Promédicaments de carbidopa et de l-dopa et leur utilisation pour traiter la maladie de parkinson
Cette divulgation concerne (a) des promedicaments de carbidopa, (b) des combinaisons et des compositions pharmaceutiques comprenant un promedicament de carbidopa et/ou un promedicament de L-dopa, etExpand